These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 27578478)

  • 1. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
    Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
    Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
    Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
    Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.
    Paggiaro P; Halpin DM; Buhl R; Engel M; Zubek VB; Blahova Z; Moroni-Zentgraf P; Pizzichini E
    J Allergy Clin Immunol Pract; 2016; 4(1):104-13.e2. PubMed ID: 26563670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.
    Szefler SJ; Murphy K; Harper T; Boner A; Laki I; Engel M; El Azzi G; Moroni-Zentgraf P; Finnigan H; Hamelmann E
    J Allergy Clin Immunol; 2017 Nov; 140(5):1277-1287. PubMed ID: 28189771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.
    Vogelberg C; Engel M; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Downie J; Nething K; Vevere V; Vandewalker M
    Respir Med; 2014 Sep; 108(9):1268-76. PubMed ID: 25081651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.
    Kew KM; Dahri K
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.
    Kerstjens HA; Moroni-Zentgraf P; Tashkin DP; Dahl R; Paggiaro P; Vandewalker M; Schmidt H; Engel M; Bateman ED
    Respir Med; 2016 Aug; 117():198-206. PubMed ID: 27492532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.
    Kerstjens HA; Casale TB; Bleecker ER; Meltzer EO; Pizzichini E; Schmidt O; Engel M; Bour L; Verkleij CB; Moroni-Zentgraf P; Bateman ED
    Lancet Respir Med; 2015 May; 3(5):367-76. PubMed ID: 25682232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of tiotropium Respimat
    Graham LM; Kerstjens HAM; Vogelberg C; Hamelmann E; Szefler SJ; Pisternick-Ruf W; Engel M; El Azzi G; Unseld A; Foggs MB
    Respir Med; 2019 Aug; 155():58-60. PubMed ID: 31302579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiotropium for the treatment of asthma in adolescents.
    Hamelmann E; Vogelberg C; Szefler SJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):305-312. PubMed ID: 28110558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.
    Vogelberg C; Szefler SJ; Vrijlandt EJLE; Boner AL; Engel M; El Azzi G; Vulcu SD; Moroni-Zentgraf PM; Eickmeier O; Hamelmann EH
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 31097514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial.
    Hamelmann E; Bateman ED; Vogelberg C; Szefler SJ; Vandewalker M; Moroni-Zentgraf P; Avis M; Unseld A; Engel M; Boner AL
    J Allergy Clin Immunol; 2016 Aug; 138(2):441-450.e8. PubMed ID: 26960245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of Asthma and Role of 2.5 µg Tiotropium Respimat
    Mansfield L; Duong-Quy S; Craig T
    Adv Ther; 2019 Oct; 36(10):2587-2599. PubMed ID: 31435830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.
    Beeh KM; Moroni-Zentgraf P; Ablinger O; Hollaenderova Z; Unseld A; Engel M; Korn S
    Respir Res; 2014 Jun; 15(1):61. PubMed ID: 24890738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists.
    McKeage K
    Drugs; 2015 May; 75(7):809-16. PubMed ID: 25895466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis.
    Wang L; Zhou R; Xie X
    J Asthma; 2019 Jan; 56(1):69-78. PubMed ID: 29420077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.
    Vrijlandt EJLE; El Azzi G; Vandewalker M; Rupp N; Harper T; Graham L; Szefler SJ; Moroni-Zentgraf P; Sharma A; Vulcu SD; Sigmund R; Chawes B; Engel M; Bisgaard H
    Lancet Respir Med; 2018 Feb; 6(2):127-137. PubMed ID: 29361462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics.
    Casale TB; Aalbers R; Bleecker ER; Meltzer EO; Zaremba-Pechmann L; de la Hoz A; Kerstjens HAM
    Respir Med; 2019; 158():97-109. PubMed ID: 31654891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.